MEBENDAZOLE

Generic	Brand	HICL	GCN	Exception/Other
MEBENDAZOLE	EMVERM		43181	

GUIDELINES FOR USE

1. Is the patient being treated for *enterobius vermicularis* (pinworm) **AND** meet the following criterion?
   - The patient has had a trial of or has a contraindication to pyrantel pamoate (OTC)

   If yes, **approve for 1 month by GPID with a quantity limit of #2 tablets per 30 days**.
   If no, continue to #2.

2. Is the patient being treated for *trichuris trichiura* (whipworm) **OR** *ascaris lumbricoides* (common roundworm) and meet ALL of the following criteria?
   - Documentation confirming a diagnosis of *trichuris trichiura* (whipworm) or *ascaris lumbricoides* (common roundworm)
   - The patient has had a trial of or has a contraindication to albendazole (Albenza)

   If yes, **approve for 1 month by GPID with a quantity limit of #6 tablets per 30 days**.
   If no, continue to #3.

3. Is the patient being treated for *ancylostoma duodenale* (common hookworm) or *necator americanus* (American hookworm) and meet **ALL** of the following criteria?
   - Documentation confirming a diagnosis of *ancylostoma duodenale* (common hookworm) or *necator americanus* (American hookworm)
   - The patient has had a trial of or has a contraindication to albendazole (Albenza) **OR** pyrantel pamoate (OTC)

   If yes, **approve for 1 month by GPID with a quantity limit of #6 tablets per 30 days.**
   If no, do not approve.
   DENIAL TEXT: The guideline named **MEBENDAZOLE (Emverm)** requires that the medication is used for the treatment of *Enterobius vermicularis* (pinworm), *trichuris trichiura* (whipworm), *ascaris lumbricoides* (common roundworm), *ancylostoma duodenale* (common hookworm), or *necator americanus* (American hookworm). The following criteria must also be met:
   For treatment of *enterobius vermicularis* (pinworm), approval requires:
   - The patient has had a trial of or has a contraindication to pyrantel pamoate (OTC)

   For treatment of trichuris trichiura (whipworm) or ascaris lumbricoides (common roundworm), approval requires:
   - Documentation confirming a diagnosis of *trichuris trichiura* (whipworm) or *ascaris lumbricoides* (common roundworm)
   - The patient has had a trial of or has a contraindication to albendazole (Albenza)

   (Denial text continued on next page)

CONTINUED ON NEXT PAGE

MEBENDAZOLE

GUIDELINES FOR USE (CONTINUED)

For treatment of ancylostoma duodenale (common hookworm) or necator americanus (American hookworm), approval requires:

- Documentation confirming a diagnosis of *ancylostoma duodenale* (common hookworm) or *necator americanus* (American hookworm)
- The patient has had a trial of or has a contraindication to albendazole (Albenza) **OR** pyrantel pamoate (OTC)

RATIONALE

To ensure appropriate use of mebendazole consistent with FDA approved use and CDC treatment guidelines.

FDA APPROVED INDICATION

Emverm (mebendazole) is indicated for the treatment of *Enterobius vermicularis* (pinworm), *Trichuris trichiura* (whipworm), *Ascaris lumbricoides* (common roundworm), *Ancylostoma duodenale* (common hookworm), *Necator americanus* (American hookworm) in single or mixed infections.

DOSAGE AND ADMINISTRATION

- Treatment of *Enterobius vermicularis* (pinworm)
  - 1 tablet (100mg), once.
  - If the patient is not cured three weeks after treatment, a second course of treatment is advised.
- Treatment of *Trichuris trichiura* (whipworm), *Ascaris lumbricoides* (common roundworm), *Ancylostoma duodenale* (common hookworm), *Necator americanus* (American hookworm)
  - 1 tablet (100mg) twice daily for three consecutive days.
  - If the patient is not cured three weeks after treatment, a second course of treatment is advised.

AVAILABLE STRENGTHS:

- Mebendazole 100mg chewable tablet

REFERENCES

- Emverm [Prescribing Information]. Horsham, PA: Amedra Pharmaceuticals LLC; September 2017. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13631e94-269d-45db-a433-2aa4f8d465c6. Accessed November 14, 2017.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective: 01/01/18
Created: 03/16
Client Approval: 12/17
P&T Approval: 10/17